<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: <z:chebi fb="0" ids="4466">Dexmedetomidine</z:chebi> has been used for purposes of anesthesia and sedation, and experimental studies have demonstrated its neuroprotective effects </plain></SENT>
<SENT sid="1" pm="."><plain>However, it has also been shown that the constriction of cerebral vessels in response to high doses of <z:chebi fb="0" ids="4466">dexmedetomidine</z:chebi> decreases cerebral blood flow </plain></SENT>
<SENT sid="2" pm="."><plain>We tested the hypothesis that <z:chebi fb="0" ids="4466">dexmedetomidine</z:chebi>-induced <z:e sem="disease" ids="C1695782" disease_type="Disease or Syndrome" abbrv="">cerebral hypoperfusion</z:e> exacerbates ischemic cerebral injury </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: The effects of <z:chebi fb="0" ids="4466">dexmedetomidine</z:chebi> on cerebral blood flow and mean arterial blood pressure were studied first </plain></SENT>
<SENT sid="4" pm="."><plain>Six rats received intravenous infusions of <z:chebi fb="0" ids="4466">dexmedetomidine</z:chebi> in doses ranging from 0.01 to 10 microg.kg(-1).min(-1) </plain></SENT>
<SENT sid="5" pm="."><plain>At the end of this phase of treatment, the alpha-2 adrenergic <z:chebi fb="68" ids="48706">antagonist</z:chebi> <z:chebi fb="0" ids="10093">yohimbine</z:chebi> was administered (3 mg.kg(-1) ip) </plain></SENT>
<SENT sid="6" pm="."><plain>Cerebral blood flow and mean arterial blood pressure were recorded continuously </plain></SENT>
<SENT sid="7" pm="."><plain>A second series of experiments was then performed using a rat model of transient middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> </plain></SENT>
<SENT sid="8" pm="."><plain>Forty-two rats received 1microg.kg(-1).min(-1) or 10 microg.kg(-1).min(-1) <z:chebi fb="0" ids="4466">dexmedetomidine</z:chebi> with or without pretreatment with either of the alpha-2 adrenergic <z:chebi fb="68" ids="48706">antagonists</z:chebi> <z:chebi fb="0" ids="10093">yohimbine</z:chebi> or <z:chebi fb="0" ids="48562">rauwolscine</z:chebi> </plain></SENT>
<SENT sid="9" pm="."><plain>Five days after middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> and reperfusion, the rat brains were removed and the <z:mpath ids='MPATH_124'>infarct</z:mpath> volumes were measured </plain></SENT>
<SENT sid="10" pm="."><plain>RESULTS: In the first protocol, increasing the dose of <z:chebi fb="0" ids="4466">dexmedetomidine</z:chebi> significantly decreased cerebral blood flow </plain></SENT>
<SENT sid="11" pm="."><plain>Mean arterial blood pressure decreased to 79.9% relative to baseline with a dose of 0.01 microg.kg(-1).min(-1) <z:chebi fb="0" ids="4466">dexmedetomidine</z:chebi>, and increased to 119.9% relative to baseline with a dose of 10 microg.kg(-1).min(-1) <z:chebi fb="0" ids="4466">dexmedetomidine</z:chebi> </plain></SENT>
<SENT sid="12" pm="."><plain>In the second protocol, the <z:mpath ids='MPATH_124'>infarct</z:mpath> volume in the control group was 9.5% of the total brain volume; the <z:mpath ids='MPATH_124'>infarct</z:mpath> volume increased to 11.3% in rats treated with 1 microg.kg(-1).min(-1) <z:chebi fb="0" ids="4466">dexmedetomidine</z:chebi> and the volume increased to 24.5% in rats treated with 10 microg.kg(-1).min(-1) <z:chebi fb="0" ids="4466">dexmedetomidine</z:chebi> </plain></SENT>
<SENT sid="13" pm="."><plain>Pretreatment with an alpha-2 adrenergic <z:chebi fb="68" ids="48706">antagonist</z:chebi>, either <z:chebi fb="0" ids="10093">yohimbine</z:chebi> or <z:chebi fb="0" ids="48562">rauwolscine</z:chebi>, reduced the size of these high-dose <z:chebi fb="0" ids="4466">dexmedetomidine</z:chebi>-induced <z:mpath ids='MPATH_124'>infarct</z:mpath> volumes </plain></SENT>
<SENT sid="14" pm="."><plain>CONCLUSION: <z:hpo ids='HP_0000822'>Hypertension</z:hpo> following the administration of high-dose <z:chebi fb="0" ids="4466">dexmedetomidine</z:chebi> is associated with <z:e sem="disease" ids="C1695782" disease_type="Disease or Syndrome" abbrv="">cerebral hypoperfusion</z:e> and the exacerbation of ischemic brain injury, possibly through alpha-2-induced cerebral vasoconstriction </plain></SENT>
</text></document>